A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of Varithena® (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence

@inproceedings{Gibson2017AMR,
  title={A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of Varithena® (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence},
  author={Kathleen D Gibson and Lowell S. Kabnick},
  booktitle={Phlebology},
  year={2017}
}
Objectives A randomized, placebo-controlled, multicenter study was conducted to evaluate the safety and efficacy of polidocanol endovenous microfoam (1%, Varithena® [polidocanol injectable foam], BTG International Ltd.). Methods Patients (n = 77) with symptomatic, visible varicose veins were randomized to treatment with either Varithena 1% or placebo. Results Varithena provided greater mean changes from Baseline in patient-reported assessments of symptoms (e.g., heaviness, achiness, swelling… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
EdemaNo subtypePruritus
Results Varithena provided greater mean changes from Baseline in patient - reported assessments of symptoms ( e.g. , heaviness , achiness , swelling , throbbing , itching [ HASTI® ] score 30.7 points vs 16.7 points , p = 0.0009 , primary endpoint ; and modified Venous Insufficiency Epidemiological and Economic Study - Quality - of - Life / Symptoms [ m - VEINES - QOL / Sym ; p < 0.001 ] ) , physician - assessed VCSS , and physician- and patient - assessed appearance compared with placebo .
PruritusNo subtypeEdema
Results Varithena provided greater mean changes from Baseline in patient - reported assessments of symptoms ( e.g. , heaviness , achiness , swelling , throbbing , itching [ HASTI® ] score 30.7 points vs 16.7 points , p = 0.0009 , primary endpoint ; and modified Venous Insufficiency Epidemiological and Economic Study - Quality - of - Life / Symptoms [ m - VEINES - QOL / Sym ; p < 0.001 ] ) , physician - assessed VCSS , and physician- and patient - assessed appearance compared with placebo .
Venous thrombus adverse events were reported as mild and generally resolved without sequelae .
Venous thrombus adverse events were reported as mild and generally resolved without sequelae .
All Topics